Developing Antithrombotic and Thrombolytic Agents: The Role of Experimental Models

  • Richard C. Becker
Part of the Developments in Cardiovascular Medicine book series (DICM, volume 193)


Thrombosis is a common and unifying phenomenon among persons with atherosclerotic coronary artery disease and occurs typically at discrete sites of vascular injury, defined pathobiologically as foci of endothelial cell disruption or dysfunction and overt atheromatous plaque rupture. Over a century ago, Rudolf Virchow suggested the now classical triad of associated factors leading to pathological thrombosis: (1) stasis of blood flow, (2) abnormalities of the blood vessel wall, and (3) a procoagulant state. Accordingly, researchers and scientists over the years have developed experimental methods that apply one or more of these sacred tenants. Models have also been developed that can be used in the study of treatments for vascular thrombosis. The recent focus has been on antithrombotic and thrombolytic agents.


Arterial Thrombosis Platelet Thrombus Thrombosis Model Coronary Thrombolysis Coronary Artery Thrombosis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Wessler S, Ward K, Ho C. Studies in incravascular coagulation III. The pathogenesis of serum-induced venous thrombosis. J Clin Invest 34:647, 1955.PubMedGoogle Scholar
  2. 2.
    Walenga LM, Petitou M, Lormeau JC, Samama M, Fareed J, Choay J. Antithrombotic activity of a synthecic heparin pentasaccharide in a rabbit stasis thrombosis model using different thrombogenic challenges. Thromb Res 46:187, 1987.PubMedCrossRefGoogle Scholar
  3. 3.
    Hladovec J. A sensitive model of venous thrombosis in rats. Thromb Res 43:539, 1986.PubMedCrossRefGoogle Scholar
  4. 4.
    Collen D, Stassen JM, Verstraete M. Thrombolysis with human extrinsic (tissue-type) plasminogen activator in rabbits with experimental jugular vein thrombosis. J Clin Invest 71:368, 1983.PubMedGoogle Scholar
  5. 5.
    Schaub RG, Simmons CA, Koecs MH, Romano PJ, II, Stewart GJ. Early events in the formation of a venous thrombus following local trauma and stasis. Lab Invest 51:218, 1984.PubMedGoogle Scholar
  6. 6.
    Stockmans F, Deckmyn H, Gruwez J, Vermylen J, Acland R. Continuous quantitative monitoring of mural, platelet-dependent, thrombus kinetics in the crushed rat femoral vein. Haemostas Thromb 425, 1991.Google Scholar
  7. 7.
    Baumgarcner HR. The role of blood flow in platelet adhesion, fibrin deposition, and formation of mural thrombi. Microvasc Res 5:167, 1973.CrossRefGoogle Scholar
  8. 8.
    Weichert W, Breddin HK, Staubesand J. Application of a laser-induced endothelial injury model in the screening of antithrombotic drugs. Semin Thromb Hemost l4(Suppl.):106, 1988.Google Scholar
  9. 9.
    Blair E, Nygren E, Cowley RA. A spiral wire technique for producing gradually occlusive coronary thrombosis. J Thorac Cardiovasc Surgery 48:476, 1964.Google Scholar
  10. 10.
    Kordenat RK, Kezdi P. Experimental intracoronary thrombosis and selective in situ lysis by catheter technique. Am Heart J 83:360, 1972.PubMedCrossRefGoogle Scholar
  11. 11.
    Bergmann SR, Fox KAA, Ter-Pogossian MM, Sobel BE, Collen D. Clot-selective coronary thrombolysis with tissue-type plasminogen activator. Science 220:1181, 1983.PubMedCrossRefGoogle Scholar
  12. 12.
    Golino P, Ashton JH, Glas-Greenwalt P, McNatt J, Buja LM, Willerson JT. Mediation of reocclusion by thromboxane A2 and serotonin after thrombolysis with tissue-type plasminogen activator in a canine preparation of coronary thrombosis. Circulation 77:678, 1988.PubMedGoogle Scholar
  13. 13.
    Bergmann SR, Lerch RA, Ludbrook PA, Welch MJ, Ter-Pogossian MM, Sobel BE. Temporal dependence of beneficial effects of coronary thrombolysis characterized by positron tomography. Am J Med 73:573, 1982.PubMedCrossRefGoogle Scholar
  14. 14.
    Van der Werf F, Jang IK, Collen D. Thrombolysis with recombinant human single chain urokinase-type plasminogen activator (rscu-PA): Dose-response in dogs with coronary artery thrombosis. J Cardiovasc Pharmacol 9:91, 1987.PubMedGoogle Scholar
  15. 15.
    Cercek B, Lew AS, Hod H, Yano J, Reddy J, Reddy NKN, Ganz W. Enhancement of thrombolysis with tissue-type plasminogen activator by pretreatment with heparin. Am J Heart 74:583, 1986.Google Scholar
  16. 16.
    Shebuski RJ, Storer BL, Fujita T. Effect of thromboxane synthase inhibition on the thtombolytic action of tissue-type plasminogen activator in a rabbit model of peripheral arterial thrombosis. Thromb Res 52:381, 1988.PubMedCrossRefGoogle Scholar
  17. 17.
    Folts JD, Crowell EB, Rowe GG. Platelet aggregation in partially obstrucred coronary arteries and their inhibition with aspirin. Clin Res 22:595A, 1974.Google Scholar
  18. 18.
    Folt JD, Rowe GG. Cyclical reductions in coronary blood flow in coronary arteries with fixed partial obstruction and their inhibition with aspirin. Fed Proc 33:413, 1974.Google Scholar
  19. 19.
    Folts JD, Crowell EB, Rowe GG. Platelet aggregation in partially obstructed vessels and its elimination with aspirin. Circulation 54:365, 1976.PubMedGoogle Scholar
  20. 20.
    Salazar AE. Experimental myocardial infarction, induction of coronary thrombosis in the intact closedchest dog. Cirr Res 9.135, 1961.Google Scholar
  21. 21.
    Bush LR, Shebuski RJ. In vivo models of arterial thrombosis and thrombolysis. FASEB J 4:3087, 1990.PubMedGoogle Scholar
  22. 22.
    Shea MJ, Driscoll EM, Romson JL, Pitt B, Lucchesi BR. Effects of OKY 1581, a thromboxane synthetase inhibitor, on coronary thrombosis in the conscious dog. Eur J Pharmacol 105:285, 1984.PubMedCrossRefGoogle Scholar
  23. 23.
    Simpson PJ, Smith JB Jr, Rosenthal G, Lucchesi BR. Reduction in the incidence of thrombosis by the thromboxane synthetase inhibitor CGS 13080 in a canine model of coronary artery injury. J Pharmacol Exp Ther 238:497, 1986.PubMedGoogle Scholar
  24. 24.
    Hook BG, Schumacher WA, Lee DL, Jolly SR, Lucchesi BR. Experimental coronary artery thrombosis in the absence of thromboxane A2 synthesis: Evidence for alternate pathways for coronary thrombosis. J Cardiovasc Pharmacol 7:174, 1985.PubMedCrossRefGoogle Scholar
  25. 25.
    Schumacher WA, Lucchesi BR. Effect of the thrmboxane synthetase inhibitor UK 37,248 (Dazoxiben) upon platelet aggregation, coronary artery thrombosis and vascular reactivity. J Pharmacol Exp Ther 227:790, 1983.PubMedGoogle Scholar
  26. 26.
    Haskel EJ, Prager NA, Sobel BE, Abendschein DR. Relative efficacy of antithrombin compaed with antiplatelet agents in accelerating coronary thrombolysis and preventing early reocclusion. Circulation 83:1048, 1991.PubMedGoogle Scholar
  27. 27.
    Hitzgerald DJ, Fitzgerald GA. Role of thrombin and thromboxane A2 in reocclusion following coronary thrombolysis with tissue-type plasminogen activator. Proc Natl Acas Sci USA 86:7585, 1989.CrossRefGoogle Scholar
  28. 28.
    Van der Giessen WJ, Harmsen E, de Tombe PP, Hugenholtz PG, Verdouw PD. Coronary thrombolysis with and without nifedipine in pigs. Basic Res Cardiol 83:258, 1988.PubMedCrossRefGoogle Scholar
  29. 29.
    Bagdy D, SzabÖ G, Barabás É, Bajusz S. Inhibition of D-MePhe-Pro-Arg-H (GYK1-14766) of thrombus growth in experimental models of thrombosis. Thromb Haemost 68:125, 1992.PubMedGoogle Scholar
  30. 30.
    Folrs JD. Experimental arterial platelet thrombosis, platelet inhibitors, and their possible clinical relevance: An update. Cardiovasc Res 6:10, 1990.Google Scholar
  31. 31.
    Folts JD, Hansing CE, Afonso S, Rowe GG. The systemic and coronary hemodynamic effects of ketamine in dogs. Br J Anaesth 47:686. 1975.PubMedCrossRefGoogle Scholar
  32. 32.
    Folts JD. Inhibition of acute in vivo platelet thrombus formation with U-63557A, a thromboxane A2 synthase inhibitor, but with renewal of thrombus formation with IV epinephrine. Circulation 74:11355, 1986.Google Scholar
  33. 33.
    Ashton JH, Golino P, McNatt JM, Buja LM, Willerson JT. Serotonin S2 and thromboxane A2.-prostaglandin H2 receptor blockades provide protection against epinephrine-induced cyclic flow variations in severely narrowed canine coronary arteries. J Am Coll Cardiol 13:755, 1989.PubMedCrossRefGoogle Scholar
  34. 34.
    Torr S, Noble MIM, Folts JD. Inhibition of acute platelet thrombosis in stenosed canine coronary arteries by the specific serotonin S2 receptor antagonist retanserin. Cardiovasc Res 26:465, 1990.CrossRefGoogle Scholar
  35. 35.
    Yasuda T, Gold HK, Fallon JT, Leinbach RC, Garabedian HD, Guerrero JL, Collen D. A canine model of coronary artery thrombosis with superimposed high grade stenosis for the investigation of rethrombosis after thrombolysis. J Am Coll Cardiol 13:1409, 1989.PubMedGoogle Scholar
  36. 36.
    Eidt JF, Allison P, Noble S, Ashton J, Golino P, McNatt J, Buja LM, Willerson JT. Thrombin is an important mediator of platelet aggregation in stenosed canine coronary arteries with endothelial injury. J Clin Invest 84:18, 1989.PubMedGoogle Scholar
  37. 37.
    Yasuda T, Gold HK, Fallon JT, Leinbach RC, Guerrero JL, Scudder LE, Kanke M, Shealy D, Ross MJ, Collen D, Coller BS. Monoclonal antibody against the platelet glycoprotein (GP) llb/ IlIa receptor prevents coronary artery reocclusion after reperfusion with recombinant tissue-type plasminogen activator in dogs. J Clin Invest 81:1284, 1988.PubMedGoogle Scholar
  38. 38.
    Gold HK, Coller BS, Yasuda T, Saito T, Fallon JT, Guerrero JL, Leinbach RC, Ziskind AA, Collen D. Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GP Ilb/IIIa antibody in a canine preparation. Circulation 77:670, 1988.PubMedGoogle Scholar
  39. 39.
    Collen D, Rong Lu H, Stassen J-M, Vreys L, Yasuda T, Bunting S, Gold HK. Antithrombotic effects and bleeding time prolongation with synthetic platelet GPIIb/IIIa inhibitors in animal models of platelet-mediated thrombosis. Thromb Haemost 71:95, 1994.PubMedGoogle Scholar
  40. 40.
    Tapparelli C, Metternich R, Gfeller P. Gafner B, Powling M. Antithrombotic activity in vivo of SDZ 217-766, a low-molecular weight thrombin inhibitor in comparison to heparin. Thromb Haemost 73:641, 1995.PubMedGoogle Scholar
  41. 41.
    Ardlie NG, Packham MA, Mustard JF. Adenosine diphosphate-induced platelet aggregation in suspension of washed rabbit platelets. Br J Pharmacol 19:7, 1970.Google Scholar
  42. 42.
    Peters RF, Lees CM, Mitchell KA, Tweed MF, Talbot MD, Wallis RB. The characterization of thrombus development in an improved model of arteriovenous shunt thrombosis in the rat and the effects of recombinant desulphatohirudin (CGP 39393), heparin, and iloprost. Thromb Haemost 65:268, 1991PubMedGoogle Scholar
  43. 43.
    Hampton JW, Matthews C. Similarities between baboon and human blood clotting. J Appl Physiol 21:1713, 1966.PubMedGoogle Scholar
  44. 44.
    Todd ME, McDevitt EL, Goldsmith El. Blood-clotting mechanisms of nonhuman primates: Choice of the baboon model to simulate man. J Med Primatol 1:132, 1972.PubMedGoogle Scholar
  45. 45.
    Harker LA, Hanson Sr. Experimental arterial throm-boembolism in baboons: Mechanism, quantitation and pharmacologic prevention. J Clin Invest 64:559, 1979.PubMedGoogle Scholar
  46. 46.
    Hanson SR, Harker LA, Ratner BD, Hoffman AS. In vivo evaluation of artificial surfaces with a nonhuman primate model of arterial thrombosis. J Lab Clin Med 95:289, 1980.PubMedGoogle Scholar
  47. 47.
    Hanson SR, Reidy MA, Hattori A, Harker LA. Pharmacologic modification of acute vascular graft thrombosis. Scanning Electron Microsc 2:773, 1982.Google Scholar
  48. 48.
    Malpass TW, Hanson Sr, Savage B, Hessel EA II, Harker LA. Prevention of acquired transient plug formation? Blood 57:736, 1981.PubMedGoogle Scholar
  49. 49.
    Hanson SR, Kotze HF, Savage B, Harker LA. Platelet interactions with Dacron Vascular grafts. Arteriosclerosis 5:595, 1985.PubMedGoogle Scholar
  50. 50.
    Callow AD, Ledig CB, O’Donnell TF, Kelly JJ, Rosenthal D, Korwin S, Hatte C, Kahn PC, Vecchione JJ, Valeri CR. A primate model for the study of the interaction of 111In-labeled baboon platelets with Dacron arterial prostheses. Ann Surg 191:363, 1980.CrossRefGoogle Scholar
  51. 51.
    Clowes AW, Gown AM, Hanson SR, Reidy MA. Mechanisms of arterial graft failure: Role of cellular proliferation in early healing of PTFE prostheses. Am J Pathol 118:43, 1985.PubMedGoogle Scholar
  52. 52.
    Reidy MA, Chao SS, Kirman TR, Clowes AW. Endothelial regeneration: Chronic nondenuding injury in baboon vascular grafts. Am J Pathol 123:432, 1986.PubMedGoogle Scholar
  53. 53.
    Clowes AW, Kirman TR, Reidy MA. Mechanisms of arterial graft healing: Rapid transmural capillary ingrowth provides a source of intimai endothelium and smooth muscle in porous PTFE prostheses. Am J Pathol 123:220, 1986.PubMedGoogle Scholar
  54. 54.
    Kelly AB, Marzec UM, Krupski W, Bass A, Cadroy Y, Hanson SR, Harker LA. Hirudin interruption of heparin-resistant arterial thrombus formation in baboons. Blood 77:1006, 1991.PubMedGoogle Scholar
  55. 55.
    Schneider PA, Hanson SR, Price TM, Harker LA. Confluent durable endothelialization of endarterectomized baboon aorta by early attachment of cultured endothelial cells. J Vasc Surg 11:365, 1990.PubMedCrossRefGoogle Scholar
  56. 56.
    Cadroy Y, Horrbett TA, Hanson SR. Discrimination between platelet-mediated and coagulation-mediated mechanisms in a model of complex thrombus formation in vivo. J Lab Clin Med 113:436, 1989.PubMedGoogle Scholar
  57. 57.
    Yokoyama T, Kelly AB, Marzec UM, Hanson SR, Kunitada S, Harker LA. Antithrombotic effects of orally active synthetic antagonist of activated factor X in nonhuman primates. Circulation 92:485, 1995.PubMedGoogle Scholar
  58. 58.
    Torem S, Schneider PA, Paxton LD, Yasuda H, Hanson SR. Factors’ Influencing Acute Thrombsis Formation on carotid artery vascular ceragts. Trans Am Soc Artif Intern Organs 34:916, 1988.Google Scholar
  59. 59.
    Hanson SR, Pareti FI, Ruggeri ZM, Kumcki TJ, Montgomery RR, Zimmerman TS, Harker LA. Effects of monoclonal antibodies against the platelet glycoprotein Ilb/IIIa complex on thrombosis and hemostasis in the baboon. J Clin Invest 81:149, 1988.PubMedCrossRefGoogle Scholar
  60. 60.
    Hanson SR, Harker LA. Vascular graft thrombus formation. Ann N Y Acad Sci 516:653, 1987.PubMedCrossRefGoogle Scholar
  61. 61.
    Hanson SR, Paxton LD, Harker LA. Iliac artery mural thrombus formation: Effect of antiplatelet therapy on 111In-platelet deposition in baboons. Arteriosclerosis 6:511, 1986.PubMedGoogle Scholar
  62. 62.
    Moake JL, Turner NA, Stathopoulos NA, Nolasco LH, Heliums JD. Involvement of large plasma von Willebrand faccor (vWF) multimers and unusually large vWF forms derived from endothelial cells in shear stress-induced platelet aggregation. J Clin Invest 78:1456, 1986.PubMedGoogle Scholar
  63. 63.
    Peterson DM, Stathopoulos NA, Giorgio TD, Heliums JD, Moake JL. Shear-induced platelet aggregation requires von Willebrand factor and platelet membrane glycoproteins Ib and IIb-IIIa. Blood 69:625, 1987.PubMedGoogle Scholar
  64. 64.
    Moake JL, Turner NA, Stathopoulos NA, Nolasco LH, Heliums JD. Shear-induced platelet aggregation can be mediated by vWF released by platelets, as well as exogenous large or unusually large vWF multimers, requires adenosine diphosphate, and is resistant to aspirin. Blood 71:1366, 1988.PubMedGoogle Scholar
  65. 65.
    Ikeda Y, Murata M, Araki Y, Watanabe K, Ando Y, Itagaki I, Mon Y, Ichitani M, Sakai K. Importance of fibrinogen and platelet membrane glycoprotein IIb/IIa in shear-induced platelet aggregation. Thromb Res 51:157, 1988.PubMedCrossRefGoogle Scholar
  66. 66.
    O’Brien JR. Shear-induced platelet aggregation. Lancet 335:711, 1990.PubMedCrossRefGoogle Scholar
  67. 67.
    Ikeda Y, Handa M, Kawano K, Kamata T, Murata M, Araki Y, Anbo H, Kawai Y, Watanabe K, Itagaki I, Sakai K, Ruggeri Z. The role of von Willebrand factor and fibrinogen in platelet aggregation under varying shear stress. J Clin Invest 87:1234, 1991.PubMedCrossRefGoogle Scholar
  68. 68.
    Chow TW, Heliums JD, Moake JL, Kroll MH. Shear stress-induced von Willebrand factor binding to platelet glycoprotein Ib initiates calcium influx associated with aggregation. Blood 80:113, 1992.PubMedGoogle Scholar
  69. 69.
    Grabowski EF, Herther KK, Didisheim P. Human vs. dog platelet adhesion to Cuprophane under controlled conditions of whole blood flow. J Lab Clin Med 88:368, 1976.PubMedGoogle Scholar
  70. 70.
    Muggli R, Baumgartner HR, Tschopp TB, Keller H. Automated microdensitometry and protein assays as a measure for platelet adhesion and aggregation on collagen-coated slides under controlled flow conditions. J Lab Clin Med 95:195, 1980.PubMedGoogle Scholar
  71. 71.
    Sakariassen KS, Aarts PAMM, de Groot PG, Houdijk WPM, Sixma JJ. A perfusion chamber developed to investigate platelet interaction in flowing blood with human vessel wall cells, their extracellular matrix and purified components. J Lab Clin Med 102:522, 1983.PubMedGoogle Scholar
  72. 72.
    Sakariassen KS, Muggli R, Baumgartner HR. Growth and stability of thrombi in flowing citrated blood: Assessment of platelet surface interaction with computer-assisted morphometry. Thromb Haemost 60:392, 1988.PubMedGoogle Scholar
  73. 73.
    Turitto VT, Baumgartner HR. Platelet interaction with subendothelium in a perfusion system: Physical role of red blood cells. Microvasc Res 9:335, 1975.PubMedCrossRefGoogle Scholar
  74. 74.
    Turitto VT, Baumgartner HR. Platelet interaction with subendothelium in flowing rabbit blood: Effect of blood shear rate. Microvasc Res 17:38, 1979.PubMedCrossRefGoogle Scholar
  75. 75.
    Turitto VT, Weiss HJ, Baumgartner HR. The effect of shear rate on platelet interaction with subendothelium exposed to citrated blood. Microvasc Res 19:352, 1980.PubMedCrossRefGoogle Scholar
  76. 76.
    Badimon L, Badimon JJ. Mechanisms of arterial thrombosis in nonparallel streamlines: Platelet thrombi grow on the apex of stenotic severely injured vessel wall. J Clin Invest 84:1134, 1989.PubMedGoogle Scholar
  77. 77.
    Lassila R, Badimon JJ, Vallabhajosula S, Badimon L. Dynamic monitoring of platelet deposition on severely damaged vessel wall in flowing blood. Arteriosclerosis 10:306, 1990.PubMedGoogle Scholar
  78. 78.
    Barstad RM, Roald HE, Turitto VT, Cui W, Sakariassen KS. A novel perfusion chamber for the study of thrombus formation in flowing native human blood at the apex of artificially made stenoses. Submitted.Google Scholar
  79. 79.
    Schoephoerster RT, Oynes F, Nunez G, Kapadvanjwala M, Dewanjee MK, Effects ot local geometry and fluid dynamics on regional platelet deposition on artificial surfaces. Arterioscler Thromb 13:1806, 1993.PubMedGoogle Scholar
  80. 80.
    Gast A, Tschopp TB, Baumgartner HR. Thrombin plays a key role in late platelet thrombus growth and/ or stability. Effect of a specific thrombin inhibitor on thrombogenesis induced by aortic subendothelium exposed to flowing rabbit blood. Arterioscler Thromb 14:1466, 1994.PubMedGoogle Scholar
  81. 81.
    Baumgartner HR, Muggli R. Adhesion and aggregation: Morphological demonstration and quantification in vivo and in vitro. In Gordon JL (ed). Platelets in Biology and Pathology. Amsterdam: Elsevier/North Holland, 1976:23.Google Scholar
  82. 82.
    Weiss HJ, Turitto VT, Baumgartner HR. Effect of shear rate on platelet interaction with subendothelium in citrated and native blood, 1: Shear dependent decrease of adhesion in von Willebrand’s disease and the Bernard-Soulier syndrome. J Lab Clin Med 92:750, 1978.PubMedGoogle Scholar
  83. 83.
    Aarts PAMM, Van Broek JATM, Kulken GDC, Sixma JJ, Heethaar RM. Velocity profiles in annular perfusion chamber measured by laser-Doppler velocimetry. J Biomech 9:203, 1984.Google Scholar
  84. 84.
    Turitto VT, Baumgartner HR. Platelet-surface interactions. In Colman RW, Hirsh J, Marder VJ, Salzman EW (eds). Hemostasis and Thrombosis: Basic Principles and Clinical Practice, 2nd ed. Philadelphia: JB Lippincott, 1987:555.Google Scholar
  85. 85.
    Badimon L, Turitto V, Rosemark JA, Badimon JJ, Fuster V. Characterization of a tubular flow chamber for studying platelet interaction with biologic and prosthetic materials: Deposition of indium 111-labeled platelets on collagen, subendothelium, and expanded polytetrafluoroethylene. J Lab Clin Med 110:706, 1987.PubMedGoogle Scholar
  86. 86.
    Badimon L, Badimon JJ. Mechanisms of arterial thrombosis in nonparallel streamlines: Platelet thrombi grow on the apex of stenotic severely injured vessel wall. Experimental study in the pig model. J Clin Invest 84:1134, 1989.PubMedGoogle Scholar
  87. 87.
    Sakariassen KS, Aarts PAMM, de Groot PG, Houdijk WPM, Sixma JJ. A perfusion chamber developed to investigate platelet interaction in flowing blood with human vessel wall cells, their extracellular matrix, and purified components. J Lab Clin Med 1983:522.Google Scholar
  88. 88.
    Barstad RM, Roald HE, Cui Y, Turitto VT, Sakariassen KS. A perfusion chamber developed to investigate thrombus formation and shear profiles in flowing native human blood at the apex of well-defined stenoses. Arterioscler Thromb 14:1984, 1994.PubMedGoogle Scholar
  89. 89.
    Weirz JI, Kuint J, Leslie B, Hirsh J. Standard and low molecular weight heparin have no effect on tissue plasminogen activator induced plasma clot lysis or fibrinogenolysis. Thromb Haemost 65:541, 1991.Google Scholar

Copyright information

© Kluwer Academic Publishers 1997

Authors and Affiliations

  • Richard C. Becker

There are no affiliations available

Personalised recommendations